Dr. David Blackburn with NERA Economic Consulting to Speak at The Knowledge Group’s ANDAs and The Hatch-Waxman Act: Cases, Trends and Developments to Watch For in 2017
New York, NY, February 28, 2017 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Dr. David Blackburn, Director with NERA Economic Consulting will speak at The Knowledge Group’s webcast entitled: “ANDAs and The Hatch-Waxman Act: Cases, Trends and Developments to Watch For in 2017.” This event is scheduled for April 4, 2017 from 12:00pm to 1:30pm (ET).
For further details, please visit: https://www.theknowledgegroup.org/andas-and-the-hatch-waxman-act-cases-trends-and-developments-to-watch-for-in-2017-live-webcast/
About Dr. David Blackburn
Dr. Blackburn's areas of expertise include intellectual property (IP), antitrust and competition policy, and econometric analysis. He conducts analyses related to the issues of commercial success and preliminary and permanent injunctions in both Inter Partes Review and Abbreviated New Drug Application (ANDA) proceedings pursuant to the Hatch-Waxman Act. Additionally, he conducts research and prepares expert reports for patent, trademark, and copyright infringement disputes, and false and misleading advertising cases.
Dr. Blackburn has represented clients in a variety of industries, including medical devices, pharmaceuticals, computer software, natural resources, industrial goods and chemicals, consumer products, entertainment, and financial services. Before joining NERA, Dr. Blackburn received his PhD in economics from Harvard University and his ScB in applied mathematics and economics, with honors, from Brown University.
About NERA Economic Consulting
NERA Economic Consulting is a global firm of experts dedicated to applying economic, finance, and quantitative principles to complex business and legal challenges. NERA's economists create strategies, studies, reports, expert testimony, and policy recommendations for government authorities and the world’s leading law firms and corporations. NERA’s clients value our ability to apply and communicate rigorous approaches clearly and convincingly, our commitment to deliver unbiased findings, and our reputation for quality and independence. Our clients rely on the integrity and skills of our unparalleled team of economists and other experts backed by the resources and reliability of one of the world’s largest economic consultancies. With its main office in New York City, NERA serves clients from more than 25 offices across North America, Europe, and Asia Pacific.
Abstract
As the growth rate for Abbreviated New Drug Application (ANDA) filings remain steadier than filing rates for other patent litigation, the pharmaceutical companies and their counsel need to keep themselves abreast of the latest issues hounding the industry. In the face of Hatch-Waxman Act and ANDA applications, the industry should be well-equipped in protecting and maximizing the value of pharmaceutical patents.
The Knowledge Group has assembled a panel of key thought leaders and practitioners to provide an opportunity to discuss the various issues surrounding the Hatch-Waxman Act and the Abbreviated New Drug Application (ANDA), which the pharmaceutical industry should watch out for in 2017. The panel of speakers will provide an in-depth discussion of the notable cases, trends, and developments. Speakers will also offer best practices in avoiding and mitigating future litigation risks.
Key topics include:
- Emerging Trends and Developments
- Recent Cases
- Potential Litigation Risks and Remedies
- Critical Issues and Implications
- Best Practices
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
For further details, please visit: https://www.theknowledgegroup.org/andas-and-the-hatch-waxman-act-cases-trends-and-developments-to-watch-for-in-2017-live-webcast/
About Dr. David Blackburn
Dr. Blackburn's areas of expertise include intellectual property (IP), antitrust and competition policy, and econometric analysis. He conducts analyses related to the issues of commercial success and preliminary and permanent injunctions in both Inter Partes Review and Abbreviated New Drug Application (ANDA) proceedings pursuant to the Hatch-Waxman Act. Additionally, he conducts research and prepares expert reports for patent, trademark, and copyright infringement disputes, and false and misleading advertising cases.
Dr. Blackburn has represented clients in a variety of industries, including medical devices, pharmaceuticals, computer software, natural resources, industrial goods and chemicals, consumer products, entertainment, and financial services. Before joining NERA, Dr. Blackburn received his PhD in economics from Harvard University and his ScB in applied mathematics and economics, with honors, from Brown University.
About NERA Economic Consulting
NERA Economic Consulting is a global firm of experts dedicated to applying economic, finance, and quantitative principles to complex business and legal challenges. NERA's economists create strategies, studies, reports, expert testimony, and policy recommendations for government authorities and the world’s leading law firms and corporations. NERA’s clients value our ability to apply and communicate rigorous approaches clearly and convincingly, our commitment to deliver unbiased findings, and our reputation for quality and independence. Our clients rely on the integrity and skills of our unparalleled team of economists and other experts backed by the resources and reliability of one of the world’s largest economic consultancies. With its main office in New York City, NERA serves clients from more than 25 offices across North America, Europe, and Asia Pacific.
Abstract
As the growth rate for Abbreviated New Drug Application (ANDA) filings remain steadier than filing rates for other patent litigation, the pharmaceutical companies and their counsel need to keep themselves abreast of the latest issues hounding the industry. In the face of Hatch-Waxman Act and ANDA applications, the industry should be well-equipped in protecting and maximizing the value of pharmaceutical patents.
The Knowledge Group has assembled a panel of key thought leaders and practitioners to provide an opportunity to discuss the various issues surrounding the Hatch-Waxman Act and the Abbreviated New Drug Application (ANDA), which the pharmaceutical industry should watch out for in 2017. The panel of speakers will provide an in-depth discussion of the notable cases, trends, and developments. Speakers will also offer best practices in avoiding and mitigating future litigation risks.
Key topics include:
- Emerging Trends and Developments
- Recent Cases
- Potential Litigation Risks and Remedies
- Critical Issues and Implications
- Best Practices
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Categories